MKS Inc.

▲ Bull Case

• ◆AI-packaging supercycle is structural, not cyclical — CoWoS-L, panel fan-out (FOPLP), and HBM4 architectures permanently raise chemistry and process-control intensity per chip; MKSI captures share asymmetrically vs. pure-play peers.
• ◆Operating leverage continues to compound — Q1 2026 EBITDA margin already 25.7%; base case reaches 31% by FY28 with peer-best margin path of 32-33% possible if advanced packaging mix exceeds plan.
• ◆Capital return inflection unlocks new buyer base — at <2x leverage (FY27), management has signaled dividend reinstatement and buybacks; this expands the institutional buyer universe and supports the premium-to-peer multiple.

▼ Bear Case

• ◆Multiple compression is the dominant risk — at ~17x forward EV/EBITDA, MKSI trades near peer ceiling. Historical cycle data shows 25%+ multiple contraction from peak in every prior cycle.
• ◆AI-capex digestion cycle in 2027 — TSMC/Samsung capex pause after current build-out completes; WFE corrects 18-20%; semi services revenue drops, dragging EBITDA and reigniting leverage anxiety.
• ◆China BIS escalation — expansion of export controls to MKSI chemistry/photonics products impairs $250-400M of revenue; China revenue currently ~10-12% of total with no easy substitute markets at scale.

“The Street's central debate has shifted to: 'Has the leverage-discount-removal-plus-AI-multiple-re-rating priced in too much of the bull case?' Bulls argue the AI infrastructure cycle is durable and chemistry intensity provides a moat justifying a sustained premium multiple. Bears argue mean reversion of sector multiples is the empirical base rate and the cycle will turn. Consensus FY26 revenue is ~$4.79B and consensus 1Y price target is ~$307 — implying Street sees current price as roughly fair.”

• ◆Q2 2026 earnings + 2H26 guidance (Aug 2026) — signals execution trajectory; revenue ≥ $1.18B
• ◆TSMC Q4 2026 capex guidance for 2027 — key signal of cycle continuation vs. digestion
• ◆Dividend reinstatement announcement (6-12M) — signals management confidence in cycle durability and unlocks new institutional buyers

• ◆Multiple compression (mean reversion) — High probability; -2 to -4 turns EV/EBITDA as historical base rate indicates every prior cycle contracted 25%+ from peak
• ◆WFE 2027 correction — Medium-High probability; -$300-500M EBITDA impact if capex cycle turns and digestion cycle begins
• ◆China BIS expansion to chemistry/photonics — Medium probability; -$200-400M revenue, -$60-120M EBITDA if export controls explicitly expand to MKSI products